Halozyme Therapeutics Inc (HALO)
38.96
+0.26
(+0.67%)
USD |
NASDAQ |
Apr 23, 16:00
38.96
0.00 (0.00%)
After-Hours: 18:27
Halozyme Therapeutics Price to Book Value: 58.96 for April 23, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| April 22, 2024 | 58.56 |
| April 19, 2024 | 58.47 |
| April 18, 2024 | 57.22 |
| April 17, 2024 | 57.53 |
| April 16, 2024 | 58.08 |
| April 15, 2024 | 58.59 |
| April 12, 2024 | 58.43 |
| April 11, 2024 | 59.50 |
| April 10, 2024 | 59.44 |
| April 09, 2024 | 60.73 |
| April 08, 2024 | 60.39 |
| April 05, 2024 | 62.15 |
| April 04, 2024 | 60.12 |
| April 03, 2024 | 60.88 |
| April 02, 2024 | 61.18 |
| April 01, 2024 | 62.53 |
| March 28, 2024 | 61.56 |
| March 27, 2024 | 61.64 |
| March 26, 2024 | 60.65 |
| March 25, 2024 | 61.17 |
| March 22, 2024 | 60.65 |
| March 21, 2024 | 60.86 |
| March 20, 2024 | 61.11 |
| March 19, 2024 | 61.76 |
| March 18, 2024 | 61.09 |
| Date | Value |
|---|---|
| March 15, 2024 | 61.83 |
| March 14, 2024 | 61.73 |
| March 13, 2024 | 62.57 |
| March 12, 2024 | 63.48 |
| March 11, 2024 | 62.35 |
| March 08, 2024 | 63.15 |
| March 07, 2024 | 63.12 |
| March 06, 2024 | 63.09 |
| March 05, 2024 | 62.66 |
| March 04, 2024 | 61.94 |
| March 01, 2024 | 62.21 |
| February 29, 2024 | 60.24 |
| February 28, 2024 | 60.06 |
| February 27, 2024 | 60.29 |
| February 26, 2024 | 60.03 |
| February 23, 2024 | 61.38 |
| February 22, 2024 | 60.11 |
| February 21, 2024 | 58.05 |
| February 20, 2024 | 54.48 |
| February 16, 2024 | 54.63 |
| February 15, 2024 | 54.34 |
| February 14, 2024 | 53.06 |
| February 13, 2024 | 52.42 |
| February 12, 2024 | 54.01 |
| February 09, 2024 | 53.68 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
8.253
Minimum
May 31 2019
108.84
Maximum
Apr 29 2021
38.37
Average
36.15
Median
Price to Book Value Benchmarks
| Johnson & Johnson | 5.241 |
| Globus Medical Inc | 1.736 |
| Denali Therapeutics Inc | 2.227 |
| AIM ImmunoTech Inc | 2.183 |
| Protalix BioTherapeutics Inc | 2.622 |
Price to Book Value Related Metrics
| PE Ratio | 18.46 |
| PS Ratio | 6.303 |
| PEG Ratio | 0.4057 |
| Price to Free Cash Flow | 14.00 |
| Price | 38.96 |
| Earnings Yield | 5.42% |
| Market Cap | 4.941B |
| PEGY Ratio | 0.4057 |
| Operating PE Ratio | 15.48 |
| Normalized PE Ratio | 20.16 |